MediWound to launch Phase III trial for venous leg ulcers
MediWound, an Israeli developer of products to treat burns and wounds using non-surgical tissue repair, said on Wednesday it ...
Interim Two-Year Follow-Up Data from the VenoValve(R) U.S. Pivotal Trial to be Presented Today at the VESS 2025 Annual Winter Meeting
Interim follow-up data indicate sustained improvements across all venous specific quality-of-life (QoL) indicators. PMA application for the VenoValve submitted in November 2024, with an FDA decision ...
Wound Debridement Market Size, Growth & Forecast 2033
Introduction Wound debridement is a critical medical procedure used to treat various types of wounds, including burns, <a target=_blank href= ...
MediWound begins pivotal Phase III trial for wound therapy
YAVNE, Israel - MediWound Ltd. (NASDAQ:MDWD), a biopharmaceutical company specializing in enzymatic therapies for tissue repair, has launched a Phase III clinical trial for its product EscharEx®, ...
Miami Herald7d
Interim Two-Year Follow-Up Data from the VenoValve(R) U.S. Pivotal Trial to be Presented Today at the VESS 2025 Annual Winter Meeting
and in the most severe cases, recurrent open sores known as venous ulcers. The disease can severely impact everyday functions such as sleeping, bathing, dressing, and walking, and is known to ...
Burn Care Market to Reach $4.32 Billion by 2031 - Exclusive Report by Meticulous Research®
According to a new market research report titled, 'Burn Care Market Size, Share, Forecast, & Trends Analysis by Offering ...